$MGNX
MACROGENICS INC Stock $mgnx

$mgnx Overview Financials Valuation SEC Filings Company Website

2022 Q3 Form 10-Q Financial Statement

#000112534522000090 Filed on August 08, 2022

Income Statement

Concept	2022 Q3	2022 Q2	2022 Q1
Revenue	$41.73M	$26.01M	$11.10M
YoY Change	166.47%	-15.44%	-34.24%
Cost Of Revenue	$3.007M	$180.0K	$48.00K
YoY Change	80.6%	718.18%	182.35%
Gross Profit	$38.73M	$25.83M	$11.05M
YoY Change	176.68%	-15.97%	-34.46%
Gross Profit Margin	92.79%	99.31%	99.57%
Selling, General & Admin	$15.36M	$13.67M	$16.25M
YoY Change	-10.52%	-10.27%	8.35%
% of Gross Profit	39.65%	52.93%	147.05%
Research & Development	$48.19M	$51.74M	$61.44M
YoY Change	-3.28%	-7.24%	15.66%
% of Gross Profit	124.44%	200.35%	555.85%
Depreciation & Amortization	$2.844M	$2.877M	$2.913M
YoY Change	1.72%	3.49%	6.74%
% of Gross Profit	7.34%	11.14%	26.35%
Operating Expenses	$48.19M	$51.74M	$61.44M
YoY Change	-3.28%	-7.24%	15.66%
Operating Profit	-$24.96M	-$41.81M	-$66.64M
YoY Change	-52.9%	3.8%	29.92%
Interest Expense	$0.00	$0.00
YoY Change
% of Operating Profit
Other Income/Expense, Net	$142.0K	$504.0K	$195.0K
YoY Change	40.59%	46.51%	828.57%
Pretax Income	-$24.81M	-$41.30M	-$66.44M
YoY Change	-53.08%	3.43%	29.52%
Income Tax
% Of Pretax Income
Net Earnings	-$24.81M	-$41.30M	-$66.44M
YoY Change	-53.08%	3.43%	29.59%
Net Earnings / Revenue	-59.46%	-158.82%	-598.53%
Basic Earnings Per Share	-$0.40	-$0.67	-$1.08
Diluted Earnings Per Share	-$0.40	-$0.67	-$1.08
COMMON SHARES
Basic Shares Outstanding	61.46M shares	61.38M shares	61.32M shares
Diluted Shares Outstanding	61.46M shares	61.38M shares	61.32M shares

Balance Sheet

Concept	2022 Q3	2022 Q2	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$123.6M	$133.7M	$184.0M
YoY Change	-58.64%	-55.02%	-46.39%
Cash & Equivalents	$83.99M	$21.47M	$47.33M
Short-Term Investments	$39.62M	$112.3M	$136.7M
Other Short-Term Assets	$9.273M	$12.56M	$14.71M
YoY Change	-48.66%	-30.06%	-19.16%
Inventory	$1.086M	$2.949M	$4.598M
Prepaid Expenses
Receivables	$13.84M	$18.39M	$14.91M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$147.8M	$167.6M	$218.2M
YoY Change	-55.84%	-54.32%	-41.77%
LONG-TERM ASSETS
Property, Plant & Equipment	$31.99M	$34.02M	$36.03M
YoY Change	-17.3%	-13.64%	-10.97%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$15.54M	$16.39M	$17.21M
YoY Change	-17.23%	-16.05%	-15.02%
Total Long-Term Assets	$47.54M	$50.41M	$53.24M
YoY Change	-17.28%	-14.44%	-12.32%
TOTAL ASSETS
Total Short-Term Assets	$147.8M	$167.6M	$218.2M
Total Long-Term Assets	$47.54M	$50.41M	$53.24M
Total Assets	$195.3M	$218.0M	$271.4M
YoY Change	-50.19%	-48.81%	-37.66%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.619M	$2.609M	$3.731M
YoY Change	-25.14%	-73.43%	-63.94%
Accrued Expenses	$33.32M	$31.76M	$32.97M
YoY Change	-20.4%	-18.92%	-5.71%
Deferred Revenue	$7.085M	$11.57M	$25.56M
YoY Change	-56.57%	-30.18%	626.19%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$50.05M	$50.88M	$67.10M
YoY Change	-27.33%	-27.24%	26.5%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$258.0K	$258.0K	$258.0K
YoY Change	0.0%	0.0%	0.0%
Total Long-Term Liabilities	$258.0K	$258.0K	$258.0K
YoY Change	0.0%	0.0%	0.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$50.05M	$50.88M	$67.10M
Total Long-Term Liabilities	$258.0K	$258.0K	$258.0K
Total Liabilities	$72.39M	$75.56M	$93.23M
YoY Change	-28.13%	-29.29%	9.79%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.106B	-$1.082B	-$1.040B
YoY Change	20.81%	25.34%	26.4%
Common Stock	$1.230B	$1.224B	$1.219B
YoY Change	1.84%	3.59%	3.86%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$123.0M	$142.5M	$178.2M
YoY Change
Total Liabilities & Shareholders Equity	$195.3M	$218.0M	$271.4M
YoY Change	-50.19%	-48.81%	-37.66%

Cashflow Statement

Concept	2022 Q3	2022 Q2	2022 Q1
OPERATING ACTIVITIES
Net Income	-$24.81M	-$41.30M	-$66.44M
YoY Change	-53.08%	3.43%	29.59%
Depreciation, Depletion And Amortization	$2.844M	$2.877M	$2.913M
YoY Change	1.72%	3.49%	6.74%
Cash From Operating Activities	-$9.422M	-$49.16M	-$57.70M
YoY Change	-36.32%	7.61%	98.71%
INVESTING ACTIVITIES
Capital Expenditures	-$804.0K	-$1.011M	$1.415M
YoY Change	-62.31%	-50.99%	126.04%
Acquisitions
YoY Change
Other Investing Activities	$72.75M	$24.05M	-$17.07M
YoY Change	-15130.99%	51.41%	-49.25%
Cash From Investing Activities	$71.95M	$23.04M	-$18.48M
YoY Change	-2849.18%	66.7%	-46.05%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$0.00
YoY Change			-100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	263.0K	$37.00K
YoY Change	-100.0%	-88.78%	-99.96%
NET CHANGE
Cash From Operating Activities	-9.422M	-49.16M	-$57.70M
Cash From Investing Activities	71.95M	23.04M	-$18.48M
Cash From Financing Activities	0.000	263.0K	$37.00K
Net Change In Cash	62.52M	-25.86M	-$76.14M
YoY Change	3905.38%	-12.4%	-303.78%
FREE CASH FLOW
Cash From Operating Activities	-$9.422M	-$49.16M	-$57.70M
Capital Expenditures	-$804.0K	-$1.011M	$1.415M
Free Cash Flow	-$8.618M	-$48.15M	-$59.11M
YoY Change	-31.94%	10.38%	99.28%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Entity Central Index Key EntityCentralIndexKey	0001125345
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-06-30
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	142481000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	239618000	usd
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-36112
	dei	Entity Registrant Name EntityRegistrantName	MACROGENICS, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	06-1591613
	dei	Entity Address Address Line1 EntityAddressAddressLine1	9704 Medical Center Drive
	dei	Entity Address City Or Town EntityAddressCityOrTown	Rockville
	dei	Entity Address State Or Province EntityAddressStateOrProvince	MD
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	20850
	dei	City Area Code CityAreaCode	301
	dei	Local Phone Number LocalPhoneNumber	251-5172
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.01 per share
	dei	Trading Symbol TradingSymbol	MGNX
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	61458790	shares
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	21469000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	123469000	usd
CY2022Q2	us-gaap	Investments Investments	112271000	usd
CY2021Q4	us-gaap	Investments Investments	120147000	usd
CY2022Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	18385000	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	10386000	usd
CY2022Q2	us-gaap	Inventory Net InventoryNet	2949000	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	4388000	usd
CY2022Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	12559000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	21170000	usd
CY2022Q2	us-gaap	Assets Current AssetsCurrent	167633000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	279560000	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	34022000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	37676000	usd
CY2022Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	16388000	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	18009000	usd
CY2022Q2	us-gaap	Assets Assets	218043000	usd
CY2021Q4	us-gaap	Assets Assets	335245000	usd
CY2022Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	2609000	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	15500000	usd
CY2022Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	31763000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	33755000	usd
CY2022Q2	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	11565000	usd
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	20646000	usd
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	4940000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	4677000	usd
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	50877000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	74578000	usd
CY2022Q2	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	6163000	usd
CY2021Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	0	usd
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	18264000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	20791000	usd
CY2022Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	258000	usd
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	258000	usd
CY2022Q2	us-gaap	Liabilities Liabilities	75562000	usd
CY2021Q4	us-gaap	Liabilities Liabilities	95627000	usd
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	125000000	shares
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	125000000	shares
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	61458790	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	61307428	shares
CY2022Q2	us-gaap	Common Stock Value CommonStockValue	615000	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	613000	usd
CY2022Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1223875000	usd
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1213002000	usd
CY2022Q2	us-gaap	Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-326000	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-61000	usd
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1081683000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-973936000	usd
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	218043000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	335245000	usd
CY2022Q2	us-gaap	Revenues Revenues	26007000	usd
CY2021Q2	us-gaap	Revenues Revenues	30757000	usd
	us-gaap	Revenues Revenues	37108000	usd
	us-gaap	Revenues Revenues	47638000	usd
CY2022Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	180000	usd
CY2021Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	22000	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	228000	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	39000	usd
CY2022Q2	mgnx	Cost Of Manufacturing Services CostOfManufacturingServices	2222000	usd
CY2021Q2	mgnx	Cost Of Manufacturing Services CostOfManufacturingServices	0	usd
	mgnx	Cost Of Manufacturing Services CostOfManufacturingServices	2222000	usd
	mgnx	Cost Of Manufacturing Services CostOfManufacturingServices	0	usd
CY2022Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	51744000	usd
CY2021Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	55780000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	113182000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	108901000	usd
CY2022Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	13669000	usd
CY2021Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	15234000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	29922000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	30270000	usd
CY2022Q2	us-gaap	Costs And Expenses CostsAndExpenses	67815000	usd
CY2021Q2	us-gaap	Costs And Expenses CostsAndExpenses	71036000	usd
	us-gaap	Costs And Expenses CostsAndExpenses	145554000	usd
	us-gaap	Costs And Expenses CostsAndExpenses	139210000	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-41808000	usd
CY2021Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-40279000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-108446000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-91572000	usd
CY2022Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	504000	usd
CY2021Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	344000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	699000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	365000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-41304000	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-39935000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-107747000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-91207000	usd
CY2022Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-43000	usd
CY2021Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-10000	usd
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-265000	usd
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	8000	usd
CY2022Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-41347000	usd
CY2021Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-39945000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-108012000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-91199000	usd
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.67
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.67
CY2021Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.66
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.66
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.76
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.76
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.56
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.56
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	61384943	shares
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	61384943	shares
CY2021Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	60068315	shares
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	60068315	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	61354721	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	61354721	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	58643496	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	58643496	shares
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	239618000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	5224000	usd
CY2022Q1	mgnx	Stock Issued During Period Value Stock Plan Activity StockIssuedDuringPeriodValueStockPlanActivity	37000	usd
CY2022Q1	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-222000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-66443000	usd
CY2022Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	178214000	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	5350000	usd
CY2022Q2	us-gaap	Stock Granted During Period Value Sharebased Compensation StockGrantedDuringPeriodValueSharebasedCompensation	264000	usd
CY2022Q2	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-43000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-41304000	usd
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	142481000	usd
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	295884000	usd
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	5243000	usd
CY2021Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	98200000	usd
CY2021Q1	mgnx	Stock Issued During Period Value Stock Plan Activity StockIssuedDuringPeriodValueStockPlanActivity	2458000	usd
CY2021Q1	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	18000	usd
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-51272000	usd
CY2021Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	350531000	usd
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	6113000	usd
CY2021Q2	us-gaap	Stock Granted During Period Value Sharebased Compensation StockGrantedDuringPeriodValueSharebasedCompensation	2346000	usd
CY2021Q2	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-10000	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-39935000	usd
CY2021Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	319045000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-107747000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-91207000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	5790000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	5510000	usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-628000	usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-808000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	974000	usd
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-1622000	usd
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-4404000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	10574000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	11356000	usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-1077000	usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	0	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	7999000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	22166000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-362000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	6476000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-8611000	usd
	us-gaap	Increase Decrease In Accounts Payable And Other Operating Liabilities IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities	-12896000	usd
	us-gaap	Increase Decrease In Accounts Payable And Other Operating Liabilities IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities	1668000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-1697000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	5365000	usd
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	75457000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-2264000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-1673000	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-2918000	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	18659000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-106857000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-74726000	usd
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	117546000	usd
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	82440000	usd
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	99800000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2426000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2693000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	4557000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-20439000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	98200000	usd
	mgnx	Proceedsfrom Stock Options Exercised And Espp Purchases ProceedsfromStockOptionsExercisedAndESPPPurchases	300000	usd
	mgnx	Proceedsfrom Stock Options Exercised And Espp Purchases ProceedsfromStockOptionsExercisedAndESPPPurchases	4804000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	300000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	103004000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-102000000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	7839000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	123469000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	181131000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	21469000	usd
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	188970000	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	295000	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	118000	usd
CY2022Q2	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	112596000	usd
CY2022Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	usd
CY2022Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	325000	usd
CY2022Q2	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	112271000	usd
CY2021Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	120208000	usd
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	usd
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	61000	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	120147000	usd
CY2021Q4	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0	usd
CY2022Q2	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0	usd
CY2022Q2	us-gaap	Inventory Work In Process InventoryWorkInProcess	2231000	usd
CY2021Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	3929000	usd
CY2022Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	718000	usd
CY2021Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	459000	usd
CY2022Q2	us-gaap	Inventory Net InventoryNet	2949000	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	4388000	usd
CY2022Q2	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	3100000	usd
CY2021Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	2000000	usd
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2017Q2	mgnx	Share Based Compensation Arrangement By Share Based Payment Award Offering Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod	P6M
CY2022Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5300000	usd
CY2021Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6070000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	10574000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	11356000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y11M12D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y3M
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	8373921	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	21.47
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y7M6D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	2685197	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	9.50
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	80721	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.48
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	267563	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	16.32
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	210079	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	23.08
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	10500755	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	18.66
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	80000	usd
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	5930958	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	22.57
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y4M24D
CY2022Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	74000	usd
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	9719165	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	19.00
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P6Y9M18D
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	79000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	6.96
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	15.11
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	500000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	1800000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	300000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	4600000	usd
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	9400000	usd
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	8100000	usd
CY2022Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	33900000	usd
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y6M

Files In Submission

Name	View Source	Status
0001125345-22-000090-index-headers.html	Edgar Link	pending
0001125345-22-000090-index.html	Edgar Link	pending
0001125345-22-000090.txt	Edgar Link	pending
0001125345-22-000090-xbrl.zip	Edgar Link	pending
exhibit101-incyte2ndamend.htm	Edgar Link	pending
exhibit31-1q22022.htm	Edgar Link	pending
exhibit31-2q22022.htm	Edgar Link	pending
exhibit32-1q22022.htm	Edgar Link	pending
exhibit32-2q22022.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
mgnx-20220630.htm	Edgar Link	pending
mgnx-20220630.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
mgnx-20220630_cal.xml	Edgar Link	unprocessable
mgnx-20220630_lab.xml	Edgar Link	unprocessable
mgnx-20220630_pre.xml	Edgar Link	unprocessable
mgnx-20220630_htm.xml	Edgar Link	completed
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
mgnx-20220630_def.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$MGNX
MACROGENICS INC Stock $mgnx

2022 Q3 Form 10-Q Financial Statement

#000112534522000090 Filed on August 08, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MGNX MACROGENICS INC Stock $mgnx

2022 Q3 Form 10-Q Financial Statement

#000112534522000090 Filed on August 08, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MGNX
MACROGENICS INC Stock $mgnx